This $807,664 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a "GigaAssay" technology by Heligenics, Inc. to create and screen large libraries of bifunctional protein chimeras with improved cell stimulatory function. The GigaAssay will be used to evaluate over 50,000 interferon chimeras, with the most effective chimeras to be confirmed in cell-based assays and tested in a mouse model of multiple sclerosis. This effort aims to develop new bifunctional protein therapeutics that are safer and more efficacious than existing monofunctional biologics. The award commenced on January 1, 2025 and is expected to be completed by December 31, 2027.
Generated 2/25/25, 5:47 AM